EUVIMEDEUVIMED entdecken
Crossref

Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

André J Scheen iD

Expert Review of Clinical Pharmacology · 2023

DOI: 10.1080/17512433.2023.2279193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von André J Scheen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Heart Failure, Atherosclerosis, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 79 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical practice. AREAS COVERED: Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven their efficacy in reducing major cardiovascular events in high-risk patients with T2DM and SGLT2is in reducing hospitalization for HF in placebo-controlled randomized trials. However, real-life studies worldwide revealed that only a minority of patients with T2DM receive either a GLP-1RA or an SGLT2i and surprisingly even less patients with established ASCVD or HF are treated with these cardioprotective antihyperglycemic agents. EXPERT OPINION: Bridging the gap between evidence-based cardiovascular protection with GLP-1RAs and SGLT2is and their underuse in daily clinical practice in patients with T2DM at high risk is crucial from a public health viewpoint. However, the task appears hazardous and the goal not attained considering the current failure. Education of specialists/primary care physicians and patients is critical. Multifaceted and coordinated interventions involving all actors (physicians, patients and broadly health-care system) must be implemented to stimulate the adoption of these cardioprotective antihyperglycemic medications as part of routine cardiovascular care among patients with T2DM. Type 2 diabetes can lead to major cardiovascular complications including cardiovascular disease linked to narrowing of the arteries (atherosclerosis), and heart failure. These complications are associated with lower quality of life and life expectancy. Thus, cardiovascular protection in people with type 2 diabetes is an important objective. However, clinical practice often fails in fully achieving this goal.Two types of medications that lower blood sugar (so-called antidiabetic agents) have shown efficacy in reducing major cardiovascular events (such as strokes and heart attacks) in high-risk patients with type 2 diabetes. One of them has also shown effectiveness in decreasing hospitalizations due to heart failure. However, in clinical practice, most patients with type 2 diabetes do not receive these medications, even people with known cardiovascular disease or heart failure, despite the proven effectiveness of these drugs. Many studies worldwide have highlighted socioeconomic inequities regarding the use of these medications, which can be expensive.From a public health perspective, it is imperative to bridge the gap between the under-use of cardioprotective antidiabetic agents in routine daily practice among high-risk patients with type 2 diabetes and the clear-cut recommendations of international guidelines. Given the current limitations, this task appears challenging. Education of physicians (both primary care practitioners and specialists, including cardiologists) and patients is most important in addressing this issue. Finally, in every country, the global health-care system should facilitate the use of these agents among patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease and heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Heart FailureAtherosclerosisCardiovascular DiseasesHumansHypoglycemic AgentsCardiotonic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseGLP-1 receptor agonistSGLT2 inhibitorcardiovascular outcome trialgliflozinheart failurereal-world clinical practice

Substanzen

Hypoglycemic AgentsCardiotonic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium.
  • Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium.

ORCID-Profile: André J Scheen

Zitieren

APA

Scheen, A. J. (2023). Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2279193

Vancouver

Scheen AJ. Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2279193

BibTeX
@article{Scheen2023,
  author = {Scheen, André J},
  title = {Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  doi = {10.1080/17512433.2023.2279193}
}
Kostenlos starten →